What’s New in the Treatment of Spinal Muscular Atrophy
PCE
English - April 18, 2023 15:00 - 12 minutes - 11.2 MB - ★★★★ - 6 ratingsCourses Education Science Life Sciences app education np education podcasts for credit app medicine pa education np medicine pa medicine ce podcasts app podcasts cme podcasts Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
In this episode, Dr. Parsons and Dr. Battista discuss current and emerging medical therapies for the treatment of spinal muscular atrophy (SMA). They review safety, efficacy, and monitoring parameters of current agents, as well as adjuct therapies in the medication pipeline. This high-level overview includes:
Review of FDA-approved medical therapies: nusinersen, onasemnogene abeparvovec-xioi, and risdiplamDiscussion of the safety, efficacy, and monitoring parameters for FDA approved medications, as well as adjuctive agents for medication therapy complicationsReview of ongoing clinical trials on anti-myostatin medications and discussion of the role these agents would play if approved by the FDAPresenters:
Julie Parsons, MD
Co-Director, Neuromuscular Clinic
Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders
Professor of Clinical Pediatrics and Neurology
Children’s Hospital Colorado
Denver, Colorado
Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, FPCN
Senior Director of Nursing, Palliative Care
Psychosocial Oncology and Palliative Care
Dana-Farber Cancer Institute
Boston, Massachusetts
Supported by an educational grant from Biogen
Link to full program:
bit.ly/41kw2dK
Link to CME: Claim credit -
bit.ly/40fkDKD